Increased serum levels of β2m-free HLA class I heavy chain in multiple myeloma

British Journal of Haematology

Volumn 106, Issue 4, 1999, Pages 987-994

  Perosa, Federico ^a   Luccarelli, Grazia ^a   Prete, Marcella ^a   Ferrone, Soldano ^b   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

2m; HLA class I heavy chain; Monoclonal gammopathy; Multiple myeloma

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

AGED; BETA 2-MICROGLOBULIN; CELLS, CULTURED; CREATININE; FEMALE; GENES, MHC CLASS I; HEMOGLOBINS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MALE; MULTIPLE MYELOMA; PLASMA CELLS;

EID: 0032883578     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1999.01635.x     Document Type: Article

References (42)

1. Alexanian, R., Barlogie, B. & Fritsche, H. (1985) Beta 2-microglobulin in multiple myeloma. American Journal of Hematology, 20, 345-551.
2. Bataille, R., Boccadoro, M., Klein, B., Durie, B. & Pileri, A. (1992) C-reactive protein and β2-microglobulin produce a simple and powerful myeloma singing system. Blood, 80, 733-737.
3. Bataille, R., Durie, B.G. & Grenier, J. (1983) Serum beta 2-microglobulin und survival duration in multiple myeloma: a simple and reliable marker for staging. British Journal of Haematology, 55, 439-447.
4. Betaille, R., Grenier, J. & Sany, J. (1984) β2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment: a prospective study of 160 patients. Blood, 63, 468-476.
5. Bernier, G.M., Cohen, R.J. & Conrad, M.E. (1968) Microglobulin-aemia in renal failure, Nature, 218, 598-599.
6. Bladé J., Rozman, C., Cervantes, F., Reverter, J.-C. & Monserrat, E. (1989) A new prognostic system for multiple myeloma based on easily available parameters. British Journal of Haematology, 72, 507-511.
7. Boccadoro, M., Gallone, G., Frieri, R. & Pileri, A. (1993) Plasma cell labeling index, beta 2-microglobulin, and C-reactive protein: what is the best combination for myeloma prognosis? Blood, 82, 3507-3508.
8. Bremming, G., Wibell, L. & Bergstrom, R. (1985) Serum β2-microglobulin at remission and relapse in patients with multiple mycloma. European Journal of Clinical Investigation, 15, 242-247.
9. Bresciani, A., Pirozri, G., Spera, M., Lombardi, M.L., Ambrosone, L., Migliaresi, S., Ferrone, S. & Manzo, C. (1998) Increased level of serum HLA class 1 antigens in patients with systemic lupus erythematosus: correlation with disease activity. Tissue Antigens, 52, 44-50.
10. Carreno, B.M. & Hansen, T.H. (1994) Exogenous peptide ligand influences the expression and half-life of free HLA class 1 heavy chains ubiquitously detected at the cell surface. European Journal of Immunology, 24, 1285-1292.
11. Child, J.A., Crawford, S.M., Norfolk, D.R., O'Quigley, J., Scarffe, J.H. & Struthers, L.P. (1983) Evaluation of serum β2-microglobulin as prognostic indicator in myclomatosis. British Journal of Cancer, 47, 111-114.
12. 2-microglobulin dissociation. Journal of Immunology, 151, 159-169.
13. Cuzick, J., Cooper, E.H. & Mac Leman, I.C. (1985) The prognostic value of serum beta 2-microglobulin compared with other presentation features in myelomatosis. British Journal of Cancer, 52, 1-6.
14. Cuzick, J., De Stavola, B.L., Cooper, E.H., Chapman, C. & MacLennan, I.C. (1990) Long-term prognostic value of serum beta 2 microglobulin in myelomatosis. British Journal of Haematology, 75, 506-510.
15. Durie, B.G. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma; correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
16. Durie, B.G. & Salmon, S.E. (1977) Multiple myeloma, macroglobulinaemia and monoclonal gammopathies. Recent Advances in Haematology (ed. by A. V. Hoffbrand, M. C. Brain and J. Hirsh). pp. 243-261. Churchill Livingstone, New York.
17. Durie, B.G., Salmon, S.E. & Moon, T.E. (1980) Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma. Blood, 55, 364-372.
18. Durie, B.C., Stock-Novack, D., Salmon, S.E., Finley, P., Beckord, J., Crowley, J. & Coltman, C.A. (1990) Prognostic value of pretreatment serum β2-microglobulin in myeloma: a Southwest Oncology Group study. Blood, 75, 823-830.
19. Ffrench, M., Ffrench, P., Remy, F., Chapuis-Cellier, C., Wolowiec, D., Ville, D. & Byron, P.A. (1995) Plasma cell proliferation in monoclonal gammopathy: relations with other biologic variables; diagnostic and prognostic significance. American Journal of Medicine, 98, 60-66.
20. Garewal, H., Durie, B.G., Kyle, R.A., Bower, B. & Serokman, R. (1994) Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders, Journal of Clinical Oncology, 2, 51-57.
21. Greipp, P.R., Katzmann, J.A., O'Fallon, W.M. & Kyle, R.A. (1988) Value of β2-microglobulin level and plasma cell labeling index as prognostic factors in patients with newly diagnosed mycloma. Blood, 72, 219-223.
22. Greipp, P.R., Lust, J.A., O'Fallon, W.M., Katzlmann, J.A., Witzig, T.E. & Kyle, R.A. (1993) Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382-3387.
23. Hamby, C.V., Kageshita, T., Wang, Z., Liang, B., Temponi, M. & Ferrone, S. (1996) Analysis of αv/β3 integrin expression by cultured human melanoma cells. Melanogenesis and Malignant. Melanoma: Biochemistry, Cell Biology. Molecular Biology, Pathophysiology. Diagnosis and Treatment (ed. by Y. Hori, V. J. Hearing and J. Nakayama), pp. 185-193. Elsevier Science, Amsterdam.
24. Heinrich, P.C., Castell, J.V. & Andus, T. (1990) Interleukin-6 and the acute phase response, Biochemical Journal, 265, 621-636.
25. Hiraki, D.D., See-Tho, K., Filvaroff, E., Krishnoswanny, S., de Bello, W., Taidi-Laskowski, B. & Grumet, F.C. (1994) Bioengineered soluble HLA B7: genesis, characterization and occurrence of dimerization. Human Immunology, 40, 235-246.
26. 4. Nuture, 227, 680-685.
27. Mandelli, F., Avvisati, G., Amadori, S., Boccadoro, M., Gernone, A., Lauta, V.M., Marmont, F., Petrucel, M.T., Tribalto, M., Vegan, M.L., Dammucco, F. & Pileri, A. (1990) Maintenance treatment with recombinant Interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. New England Journal of Medicine, 322, 1430-1434.
28. Michiels, J.J. (1992) Multiple myeloma: prognostic factors and treatment modalities. Netherlands Journal of Medicine, 40, 254-270.
29. Norfolk, D., Child, J.A., Cooper, E.H., Kerruish, S. & Ward, A.M. (1980) Serum β2-microglobulin in myelomatosis: potential value in stratification and monitoring. British Journal of Cancer, 42, 510-515.
30. Pellegrino, M.A., Ng, A.K., Russo, C., Glassy, M. & Ferrone, S. (1981) Immunochemical analysis of anti-HLA-A2, HLA-A3, and HLA-B27 xenoantisera elicited with hybrids between human and murine cells. Immunogenetics, 14, 141-152.
31. Perosa, F., Carbone, R., Ferrone, S. & Dammacco, F. (1990) Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. Journal of Immunological Methods, 128, 9-16.
32. Perosa, E., Rizzi, R., Pulpito, V. & Dammacco, F. (1995) Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific? Clinical and Experimental Immunology, 99, 16-20.
33. Pickl, W.F., Majdic, O., Faé, I., Reuschel, R., Holter, W. & Knapp, W. (1993) The soluble pool of β2-microglobulin Free HLA class I α-chains: qualitative and quantitative characterization. Journal of Immunology, 151, 2613-2622.
34. Ploegh, H.L., Orr, H.T. & Strominger, J.L. (1981) Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K. H-2D) class I molecules. Cell, 24, 287-299.
35. Puppo, E., Scudeletti, M., Indiveri, F. & Ferrone, S. (1995) Serum HLA class I antigens: markers and modulators of an immune response? Immunology Today, 16, 124-127.
36. Shardijn, G. & Statius von Eps, L. (1987) β2-microglobulin: its significance in the evaluation of renal function. Kidney International, 32, 635-641.
37. Stam, N.J., Spits, H. & Ploegh, H.J. (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chain permit biochemical characterization of certain HLA-C locus products. Journal of Immunology, 137, 2299-2306.
38. Streicher, H.Z., Cuttitta, F., Buckenmeyer, G.K., Kawamura, H., Minna, J. & Berzofsky, J.A. (1986) Mapping of the idiotopes of a monoclonal anti-myoglobin antibody with syngeneic monoclonal anti-idiotypic antibodies: detection of a common idiotype. Journal of Immunology, 136, 1007-1014.
39. Van Dobbenburgh, O.A., Rodenhuis, S., Ockhuizen, T., Wetevreden, E., Houwen, B., Fidler, V., Meijer, S. & Marrink, J. (1985) Serum beta2-microglobulin: a real improvement in the management of multiple myeloma? British Journal of Haematology, 61, 611-620.
40. Wang, Z., Hu, X.Z., Tatake, R.J., Yang, S.Y., Zeff, R.A. & Ferrone, S. (1993) Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A, and B antigens synthesized by beta 2-microglobulin gene-null F0-1 melanoma cells. Cancer Research,. 53, 4303-4309.
41. Witzig, T.E., Gonchoroff, N.J., Katzmann, J.A., Therncau, T.M., Kyle, R.A. & Greipp, P.R. (1988) Peripheral blood B cell labeling indices are a measure of disease activity in patients with monoclonal gammopathies. Journal of Clinical Oncology, 6, 104-106.
42. Zavazava, N. & Krönke, M. (1996) Soluble HLA class I molecules induce apoplosis in alloreactive cytotoxic T lymphocytes. Nature Medicine, 2, 1005-1010.